Tag: in vitro diagnostic (ivd) in cardiology and neurology market analysis

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What is the Projected CAGR for the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Size from 2025 to 2034?

The market size for in vitro diagnostic (ivd) in cardiology and neurology has been experiencing robust growth in recent years. It is projected to escalate from $15.84 billion in 2024 to $17.22 billion in 2025, equating to a compound annual growth rate (CAGR) of 8.7%. The notable expansion during the historic period is due to a heightened occurrence of age-associated cardiovascular and neurological conditions, an increasing aged population, a heightened focus on preemptive healthcare and early detection of diseases, a rising load of cardiovascular diseases (CVDs) and neurological ailments like stroke and Alzheimer’s disease, an uptick in investments in healthcare infrastructure, and a supportive regulatory landscape guiding the sanction and reimbursement of diagnostic examinations.

The market size for in vitro diagnostic (IVD) in the cardiology and neurology sector is projected to witness significant growth in the coming years, reaching$23.59 billion by 2029 with a compound annual growth rate (CAGR) of 8.2%. The anticipated growth during this period is due to the shift towards personalized medicine in the cardiology and neurology fields, amplified demand for quick and on-the-spot testing solutions, the spread of telemedicine and remote consultation services, and an increase in research initiatives. Key trends during this period comprise the emergence of liquid biopsy technologies, progress in nanotechnology, the uptake of remote monitoring devices such as implantable cardiac monitors and brain-computer interfaces, the employment of multiplex biomarker panels, breakthroughs in medical imaging techniques like MRI, CT, and PET scans, and the creation of companion diagnostics for cardiovascular and neurological medications.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15829&type=smp

What Are the Primary Drivers Supporting the Market Growth of the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

Growth in the in vitro diagnostic (IVD) in cardiology and neurology market is expected to be spurred by the burgeoning field of personalized medicine. This medical methodology individualizes healthcare decisions, practices, medical interventions, and treatments based on each patient’s unique attributes. Several factors have propelled personalized medicine’s growth, such as breakthroughs in genomics, improved understanding of illness mechanisms, patient demand for bespoke treatments, and regulatory support, among others. IVD tests in cardiology and neurology augment personalized medicine by offering invaluable insights about a person’s genetic framework and disease status, thereby aiding in devising treatment plans that are more effective with lower risks. For instance, the Personalized Medicine Coalition, a professional organization based in the US, reported that in 2022, 12 new personalized medicines, accounting for roughly 34% of all new therapies, were approved, showcasing a significant rise from previous years. Consequently, the upsurge in personalized medicines is propelling the growth of the in vitro diagnostic (IVD) in cardiology and neurology market.

Which Primary Segments of the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Are Driving Growth and Industry Transformations?

The in vitro diagnostic (ivd) in cardiology and neurologymarket covered in this report is segmented –

1) By Product Type: Instruments; Reagents And Consumables; Software And Services

2) By Technology: Immunoassays; Molecular Diagnostics; Hematology; Other Technologies

3) By End-User: Hospitals; Clinical Laboratories; Other End-Users

Subsegments:

1) By Instruments: Diagnostic Analyzers; Point-Of-Care Devices; Electrophysiology Devices

2) By Reagents And Consumables: Diagnostic Reagents; Test Kits; Assay Consumables

3) By Software And Services: Diagnostic Software; Data Management Software; IVD Consulting And Support Services

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=15829&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?# Market?

North America was the largest region in the in vitro diagnostic (IVD) in cardiology and neurology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vitro diagnostic (IVD) in cardiology and neurology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Most Significant Market Trends in the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

Chief businesses in the cardiology and neurology in vitro diagnostic (IVD) market are pioneering AI-assisted integrated epigenetic engines to improve early detection and risk evaluation of diseases. These engines exploit machine learning models and high-tech biomarker analysis methods to increase sensitivity and precision in diagnosing and tracking heart diseases, tackling key factors of disease progression. For example, in February 2023, US biotech firm Cardio Diagnostics Holdings Inc., debuted their AI-driven blood test, PrecisionCHD, geared towards the early identification of coronary heart disease (CHD). By harnessing the firm’s unified epigenetic-genetic engine, this test assesses CHD risk and aims to prevent and identify the most prevalent type of heart disease. The inventive test merges epigenetic and genetic biomarkers with machine-learning algorithms, delivering over 75% sensitivity for both genders. It correlates a patient’s biomarker profile with adjustable risk factors—major causes of CHD, such as smoking, diabetes, hypertension, and elevated cholesterol. PrecisionCHD provides a non-invasive replacement for exercise stress tests or angiograms, featuring blood samples taken in the office or at one’s residence.

View the full report here:

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostic-ivd-in-cardiology-and-neurology-global-market-report

What Parameters Are Used to Define the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

In vitro diagnostic (IVD) in cardiology and neurology refers to medical tests performed on samples such as blood, urine, or tissue outside the body to diagnose various cardiovascular and neurological conditions. These tests play a crucial role in early detection, monitoring, and treatment decisions for diseases such as heart disease, stroke, Alzheimer’s disease, and others. It also provides timely diagnostic information, guiding patient management, and improving outcomes in cardiology and neurology.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15829

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Market Size of the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market In 2029?

In recent years, the cardiology and neurology in-vitro diagnostic (IVD) market has seen substantial growth. This growth will rise from $15.84 billion in 2024 to $17.27 billion in 2025, representing a compound annual growth rate (CAGR) of 9.0%. The increase in the historical period can be credited to the growing occurrence of age-related cardiovascular and neurological disorders, an aging population, a boosted focus on preventative health care and early disease detection, and the increasing burden of cardiovascular diseases (CVDs) and neurological disorders such as stroke and Alzheimer’s disease. Additionally, augmenting investments in healthcare infrastructure and enhanced regulatory frameworks supporting the approval and reimbursement of diagnostic tests have largely contributed to the market growth.

What Growth Rate Is Forecasted for the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market by 2029?

Expectations indicate a robust expansion in the in vitro diagnostic (IVD) market for cardiology and neurology. This growth should position the market at approximately $24.07 billion by 2029, with an 8.7% compound annual growth rate (CAGR). This anticipated expansion in the forecasted timeline arises from the shift towards personalized medicine in the fields of cardiology and neurology. There’s also increased demand for swift, on-the-spot test solutions in these areas, remote consultation and telemedicine growth, and a rise in research projects. Key trends for this period include the rise of liquid biopsy technologies, improvements in nanotechnology, uptake of remote monitoring devices like implantable cardiac monitors and brain-computer interfaces, utilization of multiplex biomarker panels, advancements in medical imaging techniques like MRI, CT, and PET scans, and creation of companion diagnostics for cardiovascular and neurological medication.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15829&type=smp

Which Key Companies Are Shaping the Future of the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

Major companies operating in the in vitro diagnostic (IVD) in cardiology and neurology market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson And Company, Quest Diagnostics Incorporated, Hologic Inc., Illumina Inc., Beckman Coulter Inc., Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Instrumentation Laboratory, bioMérieux SA, Natera, Inc., Randox Laboratories Ltd., Fulgent Genetics Inc., DiaSorin S.p.A., Oxford Nanopore Technologies, Fujirebio Diagnostics Inc., Adaptive Biotechnologies, Biocartis Group NV, Agena Bioscience

Which Factors Are Driving Demand in the In Vitro Diagnostic (IVD) In Cardiology And Neurology Industry?

The proliferation of personalised healthcare is anticipated to propel the expansion of the cardiology and neurology in vitro diagnostic (IVD) market. This medical route personalises healthcare decisions, practices, treatments, and interventions to suit every individual’s unique traits. A surge in genomics, better comprehension of disease processes, demand from patients for custom treatments, and backing from regulatory bodies are some of the reasons for the continued growth of personalised healthcare. In vitro diagnostic (IVD) testing in cardiology and neurology augments personalised healthcare by providing vital information about an individual’s genetic composition and disease state, thus helping to shape custom treatment plans for enhanced effectiveness and minimised risks. For example, in 2022, 12 recently approved personalised medicines accounted for nearly 34% of all newly approved treatments, according to the Personalized Medicine Coalition, an American professional membership body. This indicated a significant increase from earlier years. Hence, the escalating number of personalised medicines is fuelling the growth of the cardiology and neurology in vitro diagnostic (IVD) market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15829&type=smp

How Is the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Segmented by Several Divisions?

The in vitro diagnostic (IVD) in cardiology and neurology market covered in this report is segmented –

1) By Product Type: Instruments, Reagents And Consumables, Software And Services

2) By Technology: Immunoassays, Molecular Diagnostics, Hematology, Other Technologies

3) By End-User: Hospitals, Clinical Laboratories, Other End-Users

Subsegments:

1) By Instruments: Diagnostic Analyzers, Point-Of-Care Devices, Electrophysiology Devices

2) By Reagents And Consumables: Diagnostic Reagents, Test Kits, Assay Consumables

3) By Software And Services: Diagnostic Software, Data Management Software, IVD Consulting And Support Services

What are the Emerging Market Trends Driving the Growth of the In Vitro Diagnostic (IVD) In Cardiology And Neurology Industry?

Leading firms in the in vitro diagnostic (IVD) space for cardiology and neurology are turning to AI-powered integrated epigenetic systems for the early identification and evaluation of diseases. These systems take advantage of advanced machine learning models and biomarker assessment processes to improve both the sensitivity and precision of diagnoses and monitoring for heart diseases, effectively addressing key factors leading to disease advancement. For example, in February 2023, US-based biotech firm Cardio Diagnostics Holdings Inc. introduced PrecisionCHD, an AI-powered blood test for the early diagnosis of coronary heart disease (CHD). The test uses the company’s unique integrated epigenetic-genetic engine to gauge CHD risk with the goal of preventing and detecting the most widespread form of heart disease. This innovative test blends epigenetic and genetic biomarkers with machine learning algorithms, boasting over 75% accuracy in both males and females. It correlates a patient’s biomarker profile with alterable risk factors, significant causes of CHD like smoking, diabetes, hypertension, and elevated cholesterol levels. PrecisionCHD provides a non-invasive substitute for exercise stress tests or angiograms, requiring only blood samples that can be collected either in a doctor’s office or at the patient’s home.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostic-ivd-in-cardiology-and-neurology-global-market-report

Which Regions Are Driving Growth in the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

North America was the largest region in the in vitro diagnostic (IVD) in cardiology and neurology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vitro diagnostic (IVD) in cardiology and neurology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15829

This Report Delivers Insight On:

1. How big is the in vitro diagnostic (ivd) in cardiology and neurology market, and how is it changing globally?

2. Who are the major companies in the in vitro diagnostic (ivd) in cardiology and neurology market, and how are they performing?

3. What are the key opportunities and risks in the in vitro diagnostic (ivd) in cardiology and neurology market right now?

4. Which products or customer segments are growing the most in the in vitro diagnostic (ivd) in cardiology and neurology market?

5. What factors are helping or slowing down the growth of the in vitro diagnostic (ivd) in cardiology and neurology market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the in vitro diagnostic (ivd) in cardiology and neurology industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Are the Key Milestones in the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market’s Growth Trajectory From 2025 To 2034?

The cardiology and neurology segments of the in vitro diagnostic (IVD) market have seen robust growth in recent years. From 2024’s $15.84 billion, the market is predicted to reach $17.27 billion in 2025, marking an impressive compound annual growth rate (CAGR) of 9.0%. The increase in the past period can be traced back to several factors. These include a higher incidence of age-related cardiovascular and neurological conditions, a rise in the aging population, a growing focus on early disease detection and preventive healthcare, a greater incidence of cardiovascular diseases (CVDs) like stroke and Alzheimer’s disease, higher investment in healthcare infrastructure, as well as supportive regulatory environments that facilitate the approval and reimbursement of diagnostic tests.

The market size for in vitro diagnostic (IVD) within the fields of cardiology and neurology is projected to experience robust growth in the coming years, with values expected to reach $24.07 billion by 2029 at a compounded annual growth rate of 8.7%. This expected market growth during the forecast period can be credited to a myriad of factors including a shift toward personalised medicine within cardiology and neurology, a mounting demand for faster on-site testing solutions, the rise of telemedicine and virtual consultation services, as well as an increase in research imperatives. The upcoming trends for the forecast period revolve around the emergence of liquid biopsy technologies, breakthroughs in nanotechnology, increasing use of remote monitoring gadgets like implantable cardiac monitors and brain-computer interfaces, the employment of multiplex biomarker panels, innovative strides in medical imaging modalities, like MRI, CT, and PET scans, and the formulation of companion diagnostics for cardiovascular and neurological drugs.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15829&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

The in vitro diagnostic (IVD) market for cardiology and neurology is poised for significant growth, propelled by the burgeoning field of personalized medicine. Personalized medicine customizes healthcare decisions, practices, procedures, and treatments to fit the individual patient’s unique characteristics. It is a field seeing rapid growth due to advancements in genomics, a better understanding of how diseases work, patients demanding treatments customized for them, and backing from regulatory bodies, among other factors. IVD tests play a key role in personalized medicine within cardiology and neurology by providing critical data on a person’s genetic configuration and disease state, which assists in formulating custom treatment plans for better results and fewer risks. To illustrate, the Personalized Medicine Coalition, a professional organization based in the U.S, stated that in 2022, around 34% of all newly approved therapies, equating to 12 new personalized medicines, indicated a marked increase from previous years. Thus, the surge in personalized medicines is stimulating the growth of the in vitro diagnostic (IVD) in cardiology and neurology market.

Which Primary Segments of the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Are Driving Growth and Industry Transformations?

The in vitro diagnostic (IVD) in cardiology and neurology market covered in this report is segmented –

1) By Product Type: Instruments, Reagents And Consumables, Software And Services

2) By Technology: Immunoassays, Molecular Diagnostics, Hematology, Other Technologies

3) By End-User: Hospitals, Clinical Laboratories, Other End-Users

Subsegments:

1) By Instruments: Diagnostic Analyzers, Point-Of-Care Devices, Electrophysiology Devices

2) By Reagents And Consumables: Diagnostic Reagents, Test Kits, Assay Consumables

3) By Software And Services: Diagnostic Software, Data Management Software, IVD Consulting And Support Services

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=15829&type=smp

What Are the Fastest-Growing Geographies in the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

North America was the largest region in the in vitro diagnostic (IVD) in cardiology and neurology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vitro diagnostic (IVD) in cardiology and neurology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Emerging Trends that Are Influencing the In Vitro Diagnostic (IVD) In Cardiology And Neurology Industry Evolution?

Key players in the cardiologic and neurologic segments of the in vitro diagnostic (IVD) marketplace are advancing AI-integrated epigenetics mechanisms, specifically designed to detect diseases earlier and accurately assess risks. These cutting-edge engines employ machine learning algorithms and sophisticated biomarker analysis methodologies to increase precision and sensitivity in diagnosing and monitoring heart diseases, addressing significant factors instigating disease development. In particular, Cardio Diagnostics Holdings Inc., an American biotech firm, introduced an AI-powered blood test named PrecisionCHD in February 2023. This test was developed for early identification of coronary heart disease (CHD) and relied on the company’s holistic epigenetic-genetic engine to gauge CHD risk with the intention to preempt and pinpoint the most frequent type of cardiovascular ailment. By amalgamating epigenetic and genetic biomarkers with machine learning models, this new test ensures above 75% accuracy for both genders. It connects a patient’s biomarker tendency with alterable risk elements, which are primary triggers for CHD such as smoking, diabetes, hypertension, and heightened cholesterol levels. The PrecisionCHD presents a non-intrusive option as opposed to angiograms or exercise stress tests, whilst blood samples can be collected at the comfort of patients’ homes or in clinics.

View the full report here:

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostic-ivd-in-cardiology-and-neurology-global-market-report

What Parameters Are Used to Define the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

In vitro diagnostic (IVD) in cardiology and neurology refers to medical tests performed on samples such as blood, urine, or tissue outside the body to diagnose various cardiovascular and neurological conditions. These tests play a crucial role in early detection, monitoring, and treatment decisions for diseases such as heart disease, stroke, Alzheimer’s disease, and others. It also provides timely diagnostic information, guiding patient management, and improving outcomes in cardiology and neurology.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15829

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theIn Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

The in vitro diagnostic (IVD) in cardiology and neurology market is set to expand, fueled by the growth of personalized medicine. This type of medicine customizes medical decisions, procedures, interventions, and treatments specific to each patient’s unique characteristics. The expansion of personalized medicine can be attributed to advancements in genomics, enhanced understanding of disease mechanisms, patient demand for customized treatments, and regulatory support, among other things. Personalized healthcare is facilitated by in vitro diagnostic (IVD) tests in cardiology and neurology, which provide essential information about a person’s genetic composition and health condition, thereby guiding personalized treatment strategies for heightened efficacy and reduced dangers. For example, the Personalized Medicine Coalition, a professional membership organization based in the US, reported in 2022, that the approval of 12 new personalized medicines made up roughly 34% of all newly approved therapies, marking a significant increase from prior years. Consequently, the rising number of personalized medicines is propelling the growth of the in vitro diagnostic (IVD) in cardiology and neurology market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15829&type=smp

#How Will the CAGR of the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Influence Its Overall Growth by 2034?

There has been significant growth in the size of the in vitro diagnostic (IVD) market for cardiology and neurology in recent years. The market, which was valued at $15.84 billion in 2024, is projected to reach $17.27 billion in 2025 with a compound annual growth rate (CAGR) of 9.0%. This historic growth can be tied to factors such as an increase in age-related cardiovascular and neurological disorders, a rising aging population, a growing focus on preventive healthcare and early detection of diseases, an escalating burden of cardiovascular diseases (CVDs) and neurological disorders like stroke and Alzheimer’s disease, an increase in healthcare infrastructure investment, and a supportive regulatory framework that oversees the approval and reimbursement of diagnostic tests.

The market for in vitro diagnostic (IVD) in the disciplines of cardiology and neurology is projected to experience robust growth in the coming years, reaching a worth of $24.07 billion by 2029 with a compound annual growth rate (CAGR) of 8.7%. This anticipated growth over the forecast period can be linked to various factors including the move towards personalized medicine in both fields, an increased desire for quick and localized testing solutions, the broadening of telemedicine and remote consultation services, and a surge in research efforts. Key trends for the forecast period involve the emergence of liquid biopsy technologies, progress in nanotechnology, the adoption of remote monitoring devices like implantable cardiac monitors and brain-computer interfaces, the application of multiplex biomarker panels, breakthroughs in medical imaging methods such as MRI, CT, and PET scans, as well as the creation of companion diagnostics for cardiovascular and neurological medications.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15829

What Are the Current Market Growth and Trends in theIn Vitro Diagnostic (IVD) In Cardiology And Neurology Market That Industry Players Should Watch?

Leading enterprises in the cardiology and neurology (IVD) in vitro diagnostic market are constructing artificial intelligence(AI)-worked incorporated epigenetic frameworks for early disease recognition and risk evaluation. These AI-based engines employ machine-learning models and superior biomarker review methods to enhance precision and sensitivity in diagnosis and supervision of cardiovascular diseases, thus confronting major disease progression factors. For example, Cardio Diagnostics Holdings Inc., a biotech firm from the US, introduced PrecisionCHD in February 2023. It’s an AI-powered blood test designed for the early detection of coronary heart disease (CHD). With the assistance of the organization’s consolidated epigenetic-genetic engine, this test intends to detect and avert the most frequent form of cardiovascular disease. PrecisionCHD merges epigenetic and genetic biomarkers with machine-learning algorithms, administering over 75% sensitivity in both genders. It associates a patient’s biomarker profile to changeable risk factors, which are substantial contributors to CHD, such as smoking, diabetes, high blood pressure, and elevated cholesterol levels. As a non-invasive alternative to exercise stress trials or angiograms, PrecisionCHD permits the collection of blood samples in-office or at a patient’s residence.

What Are the Major Market Players Making an Impact on theIn Vitro Diagnostic (IVD) In Cardiology And Neurology Market Growth?

Major companies operating in the in vitro diagnostic (IVD) in cardiology and neurology market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson And Company, Quest Diagnostics Incorporated, Hologic Inc., Illumina Inc., Beckman Coulter Inc., Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Instrumentation Laboratory, bioMérieux SA, Natera, Inc., Randox Laboratories Ltd., Fulgent Genetics Inc., DiaSorin S.p.A., Oxford Nanopore Technologies, Fujirebio Diagnostics Inc., Adaptive Biotechnologies, Biocartis Group NV, Agena Bioscience

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostic-ivd-in-cardiology-and-neurology-global-market-report

How Are the Key Segments of the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Driving Opportunities and Innovations?

The in vitro diagnostic (IVD) in cardiology and neurology market covered in this report is segmented –

1) By Product Type: Instruments, Reagents And Consumables, Software And Services

2) By Technology: Immunoassays, Molecular Diagnostics, Hematology, Other Technologies

3) By End-User: Hospitals, Clinical Laboratories, Other End-Users

Subsegments:

1) By Instruments: Diagnostic Analyzers, Point-Of-Care Devices, Electrophysiology Devices

2) By Reagents And Consumables: Diagnostic Reagents, Test Kits, Assay Consumables

3) By Software And Services: Diagnostic Software, Data Management Software, IVD Consulting And Support Services

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=15829&type=smp

What Regions Are At the Forefront of #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theIn Vitro Diagnostic (IVD) In Cardiology And Neurology Market?# Market Expansion?

North America was the largest region in the in vitro diagnostic (IVD) in cardiology and neurology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vitro diagnostic (IVD) in cardiology and neurology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global In Vitro Diagnostic (IVD) In Cardiology And Neurology Market 2025, By The Business Research Company:

Medical Image Management Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/medical-image-management-global-market-report

Image Guided Surgery Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/image-guided-surgery-devices-global-market-report

Artificial Intelligence (AI) Image Recognition Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-image-recognition-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the in vitro diagnostic (ivd) in cardiology and neurology market?

The market size for in-vitro diagnostic (IVD) in the field of Cardiology and Neurology has experienced substantial growth in the past few years. An increase from $15.84 billion in 2024 to $17.27 billion in 2025 is expected, indicating a compound annual growth rate (CAGR) of 9.0%. The upward trend in the past can be linked to several factors including an increase in age-related cardiovascular and neurological conditions, a rise in the elderly population, an enhanced focus on preventative healthcare and early disease detection. Other contributing factors are the escalating burden of cardiovascular diseases (CVDs) and neurological conditions like stroke and Alzheimer’s disease, the growth in healthcare infrastructure investments, and an increase in the supportive regulatory frameworks that oversee the approval and reimbursement of diagnostic tests.

What will be the in vitro diagnostic (ivd) in cardiology and neurology market size in the future?

The market for in vitro diagnostic (IVD) specific to cardiology and neurology is forecasted to witness significant growth in the upcoming years, with an anticipated value of $24.07 billion in 2029, growing at a compound annual growth rate (CAGR) of 8.7%. This surge during the forecast period is attributed to multiple factors including the evolving trend towards personalized medicine within cardiology and neurology, an escalating demand for swift and on-site diagnostic solutions in these spheres, the broadening scope of telemedicine and remote consultation services, and a rise in research initiatives. Major trends that will shape the forecast period include the emergence of liquid biopsy technologies, progress in nanotechnology, the utilization of remote monitoring devices, such as implantable cardiac monitors and brain-computer interfaces, application of multiplex biomarker panels, breakthroughs in medical imaging modalities, such as MRI, CT, and PET scans, and the development of companion diagnostics for cardiovascular and neurological drugs.

Get your in vitro diagnostic (ivd) in cardiology and neurology market report here!

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostic-ivd-in-cardiology-and-neurology-global-market-report

What main drivers are fueling expansion in the in vitro diagnostic (ivd) in cardiology and neurology market?

The surge in personalized medicine is predicted to catalyze the growth of the in vitro diagnostic (IVD) market in cardiology and neurology sectors. Personalized medicine entails a healthcare approach guided by the unique attributes of each patient, insofar as making health decisions, executing practices, conducting interventions, and adopting treatments. The expansion of personalized medicine can be attributed to leaps in genomics, deeper understanding of disease processes, patient interest in customized treatments, and regulatory backing, among other elements. In vitro diagnostic (IVD) testing for cardiology and neurology aids personalized medicine by offering vital insight into a patient’s genetic composition and condition status, steering personalized treatment methods for better effectiveness and minimal risks. For instance, as indicated by the Personalized Medicine Coalition, a professional membership organization based in the US, in 2022, the sanctioning of 12 new personalized medicines accounted for about 34% of all freshly approved treatments, marking a significant jump from earlier years. Consequently, the proliferating number of personalized medicines is propelling the growth of the in vitro diagnostic (IVD) in cardiology and neurology market.

What key areas define the segmentation of the global in vitro diagnostic (ivd) in cardiology and neurology market?

The in vitro diagnostic (IVD) in cardiology and neurology market covered in this report is segmented –

1) By Product Type: Instruments, Reagents And Consumables, Software And Services

2) By Technology: Immunoassays, Molecular Diagnostics, Hematology, Other Technologies

3) By End-User: Hospitals, Clinical Laboratories, Other End-Users

Subsegments:

1) By Instruments: Diagnostic Analyzers, Point-Of-Care Devices, Electrophysiology Devices

2) By Reagents And Consumables: Diagnostic Reagents, Test Kits, Assay Consumables

3) By Software And Services: Diagnostic Software, Data Management Software, IVD Consulting And Support Services

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15829&type=smp

Who are the dominant players expanding their reach in the in vitro diagnostic (ivd) in cardiology and neurology market?

Major companies operating in the in vitro diagnostic (IVD) in cardiology and neurology market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson And Company, Quest Diagnostics Incorporated, Hologic Inc., Illumina Inc., Beckman Coulter Inc., Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Instrumentation Laboratory, bioMérieux SA, Natera, Inc., Randox Laboratories Ltd., Fulgent Genetics Inc., DiaSorin S.p.A., Oxford Nanopore Technologies, Fujirebio Diagnostics Inc., Adaptive Biotechnologies, Biocartis Group NV, Agena Bioscience

What are the key trends shaping the future of the in vitro diagnostic (ivd) in cardiology and neurology market?

Leading firms in the cardiology and neurology in vitro diagnostic (IVD) market are leveraging artificial intelligence (AI) to develop integrated epigenetic engines for early disease detection and risk evaluation. These engines use machine learning models and sophisticated biomarker analysis techniques to increase the precision and sensitivity in diagnosing and monitoring heart-related diseases, thus addressing critical factors in disease progression. For example, Cardio Diagnostics Holdings Inc., a biotechnology firm based in the US, introduced an AI-powered blood test named PrecisionCHD in February 2023, designed specifically for the early detection of coronary heart disease (CHD). This test utilizes the company’s advanced epigenetic-genetic engine to assess CHD risk and aims at preventing and diagnosing the most prevalent form of heart disease. It merges epigenetic and genetic biomarkers with machine-learning algorithms, achieving over 75% sensitivity for both genders. The test connects a patient’s biomarker profile with changeable risk factors that contribute mainly to CHD, such as smoking, diabetes, hypertension and high cholesterol. PrecisionCHD serves as a non-invasive substitute to exercise stress tests or angiograms, allowing blood samples to be collected either at a medical office or at home.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15829

Which regions are emerging as leaders in the in vitro diagnostic (ivd) in cardiology and neurology market?

North America was the largest region in the in vitro diagnostic (IVD) in cardiology and neurology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vitro diagnostic (IVD) in cardiology and neurology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Medical Image Management Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/medical-image-management-global-market-report

Image Guided Surgery Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/image-guided-surgery-devices-global-market-report

Artificial Intelligence (AI) Image Recognition Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-image-recognition-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Factors Are Driving the Anticipated Growth Rate of the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Through 2034?

The market size of in vitro diagnostic (IVD) in the sectors of cardiology and neurology has been on an upward trend in the recent past. The market is predicted to rise from $15.84 billion in 2024 to $17.27 billion in 2025, boasting a Compound Annual Growth Rate (CAGR) of 9.0%. The growth witnessed during the historic period is attributable to an increase in prevalence of cardiovascular and neurological disorders associated with aging, a rising aging population, and an increased focus on preventive healthcare and early detection of diseases. Other contributing factors include an escalating incidence of cardiovascular and neurological conditions such as stroke and Alzheimer’s disease, increased healthcare infrastructure investment, and supportive regulatory frameworks that govern diagnostic test approval and reimbursement.

There is an anticipation for robust expansion in the in vitro diagnostic (IVD) market related to cardiology and neurology in the coming years. The forecast suggests an escalation to $24.07 billion by 2029, with a compound annual growth rate (CAGR) of 8.7%. The propulsion in the growth during this projected period can be linked to the move towards personalized medicine in cardiology and neurology, the rising necessity for quick and local testing solutions in these areas, proliferation of telemedicine and remote consultation services, and an increase in research endeavors. Key upcoming trends for this period encompass the advent of liquid biopsy technologies, breakthroughs in nanotechnology, the integration of remote monitoring devices like implantable cardiac monitors and brain-computer interfaces, application of multiplex biomarker panels, innovations in medical imaging techniques such as MRI, CT, and PET scans, and the evolution of companion diagnostics for cardiovascular and neurological medication.

What Factors Are Propelling the Growth of the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market from 2025 to 2034?

The surge in personalized medicine is set to drive the growth of the market for in vitro diagnostics (IVD) in cardiology and neurology. Personalized medicine, which supports healthcare decisions, strategies, interventions and treatments tailored to each patient’s unique characteristics, is growing due to developments in genomics, a deeper understanding of how diseases work, consumer demand for personalized treatments, and regulatory support, among other things. In vitro diagnostic (IVD) tests in the fields of cardiology and neurology play a vital role in promoting personalized medicine, offering key insights into a person’s genetic makeup and disease condition, therefore enabling the creation of customized treatment protocols for better effectiveness and decreased risks. For example, the Personalized Medicine Coalition, a professional membership group based in the United States, reported that in 2022, the approval of 12 new personalized medicines amounted to about 34% of all new therapy approvals, signifying a significant upward trend compared to previous years. Consequently, the growth in the number of personalized medicines is promoting the expansion of the in vitro diagnostic (IVD) in cardiology and neurology market.

Get Your Free Sample of the Global In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=15829&type=smp

Who Are the Major Industry Leaders Accelerating Growth in the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

Major companies operating in the in vitro diagnostic (IVD) in cardiology and neurology market are:

• F. Hoffmann-La Roche Ltd._x000D_

• Thermo Fisher Scientific Inc._x000D_

• Abbott Laboratories_x000D_

• Danaher Corporation_x000D_

• Siemens Healthineers AG_x000D_

Which Current Trends Are Having the Most Impact on the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

Major firms in the cardiology and neurology sector of in vitro diagnostic (IVD) are capitalizing on AI-powered integrated epigenetic systems for early detection of diseases and risk analysis. These advanced systems use machine learning models and sophisticated biomarker examination methods to augment accuracy and sensitivity in spotting and overseeing cardiovascular diseases. These play a crucial role addressing significant triggers of disease advancement. For example, in February 2023, a US biotechnology firm, Cardio Diagnostics Holdings Inc., introduced PrecisionCHD, an AI-empowered blood test crafted for early detection of coronary heart disease (CHD). By leveraging the company’s inclusive epigenetic-genetic engine, this test assesses CHD risk with the intention of early detection and prevention of the most prevalent type of cardiovascular disease. The new test amalgamates epigenetic and genetic biomarkers with machine-learning algorithms, achieving over 75% sensitivity in both men and women. It associates a patient’s biomarker profile with adjustable risk factors, key inducers of CHD, such as smoking, diabetes, hypertension, and high cholesterol levels. PrecisionCHD poses as a non-invasive alternate to exercise stress tests or angiograms, allowing for blood samples to be taken either at the doctor’s office or at home.

Get Instant Access to the Global In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostic-ivd-in-cardiology-and-neurology-global-market-report

What Major Market Segments Define the Scope and Growth of the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

The in vitro diagnostic (IVD) in cardiology and neurology market covered in this report is segmented –

1) By Product Type: Instruments, Reagents And Consumables, Software And Services

2) By Technology: Immunoassays, Molecular Diagnostics, Hematology, Other Technologies

3) By End-User: Hospitals, Clinical Laboratories, Other End-Users

Subsegments:

1) By Instruments: Diagnostic Analyzers, Point-Of-Care Devices, Electrophysiology Devices

2) By Reagents And Consumables: Diagnostic Reagents, Test Kits, Assay Consumables

3) By Software And Services: Diagnostic Software, Data Management Software, IVD Consulting And Support Services

Which Regions Are Key Players in the Growth of the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

North America was the largest region in the in vitro diagnostic (IVD) in cardiology and neurology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vitro diagnostic (IVD) in cardiology and neurology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Elements Shape the Definition of the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

In vitro diagnostic (IVD) in cardiology and neurology refers to medical tests performed on samples such as blood, urine, or tissue outside the body to diagnose various cardiovascular and neurological conditions. These tests play a crucial role in early detection, monitoring, and treatment decisions for diseases such as heart disease, stroke, Alzheimer’s disease, and others. It also provides timely diagnostic information, guiding patient management, and improving outcomes in cardiology and neurology.

Browse Through More Similar Reports By The Business Research Company:

Medical Image Management Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/medical-image-management-global-market-report

Image Guided Surgery Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/image-guided-surgery-devices-global-market-report

Artificial Intelligence (AI) Image Recognition Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-image-recognition-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: